A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-α inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients DOI Creative Commons

E. Mahmoud,

Abdullah Radwan,

Sahar A. Elsayed

et al.

Clinical Rheumatology, Journal Year: 2024, Volume and Issue: 43(12), P. 3657 - 3668

Published: Oct. 31, 2024

Abstract To evaluate the efficacy of baricitinib compared to TNF-α Inhibitors and conventional DMARDs (cDMARDs) in patients with RA. Our study included 334 RA classified into 3 groups: first receiving baricitinib, second Inhibitors, third cDMARDs. Patients were evaluated at baseline, week 12, 24 using TJC, SJC, VAS, DAS28, CDAI, HAQ-DI. Larsen score was measured baseline weeks. The response therapy assessed weeks 12 ACR 20, 50, 70 criteria. Emerging treatment side effects monitored. showed significant improvement regarding all outcome measures 24. In addition, comparable TNF except which higher group. Furthermore, group significantly better comparison cDMARDs most common infection, GIT, CVS complications. inhibitors infection skin had least effects, mostly GIT Baricitinib is an effective drug for treating refractory cDMARDs, improving disease activity functional status reducing progression structural joint damage. It has a safety profile Inhibitors. Multicenter studies are recommended support our results. Key Points • therapeutic choice rheumatoid arthritis treated status. Bricitinib delayed radiographic damage more effectively than that inhibitors.

Language: Английский

Suberosin attenuates rheumatoid arthritis by repolarizing macrophages and inhibiting synovitis via the JAK/STAT signaling pathway DOI Creative Commons
Huan Liu, Qianwei Li, Yuehong Chen

et al.

Arthritis Research & Therapy, Journal Year: 2025, Volume and Issue: 27(1)

Published: Jan. 21, 2025

Rheumatoid arthritis (RA) is a systemic disease that primarily manifests as chronic synovitis of the symmetric small joints. Despite availability various targeted drugs for RA, these treatments are limited by adverse reactions, warranting new treatment approaches. Suberosin (SBR), isolated from Plumbago zeylanica—a medicinal plant traditionally used to treat RA in Asia—possesses notable biological activities. This study aimed investigate effects and potential underlying pathways SBR on RA. Tumor necrosis factor-alpha (TNF-α) induced inflammation RA-derived fibroblast-like synoviocytes (RA-FLS), expression proinflammatory mediators was assessed using q-RT PCR ELISA after with concentrations. Bone marrow-derived macrophages (BMDMs) were differentiate into M1 M2 macrophages, followed concentrations macrophage polarization assessment. Low-dose (0.5 mg/kg/d) high-dose (2 regimens administered collagen-induced (CIA) mouse model 21 days, anti-arthritic evaluated. Network pharmacology molecular docking analyses predict targets SBR. The effect Janus kinase/signal transducer activator transcription (JAK/STAT) pathway suppressed toward phenotype while enhancing their phenotype. reduced levels TNF-α-induced RA-FLS. Mechanistically, inhibited phosphorylation JAK1/STAT3 signaling RA-FLS promoted JAK1/STAT6 polarization. In vivo, prophylactic low-dose infiltration synovial tissue, increased proportion decreased inflammatory serum alleviating inflammation. significantly alleviated CIA mice through repolarization inhibition clinical symptoms, joint pathological damage, cytokine mice. exhibited via pathways, inhibiting tissue promoting Therefore, may be an effective candidate treatment.

Language: Английский

Citations

0
Ghrelin/GHSR system attenuates collagen-induced arthritis in mice and ameliorates inflammation in human rheumatoid arthritis fibroblast-like synoviocytes DOI
Junxian Ma, Jinshan Zhang, Jie Liu

et al.

Biochemical Pharmacology, Journal Year: 2025, Volume and Issue: 238, P. 116973 - 116973

Published: May 6, 2025

Language: Английский

Citations

0
Siweixizangmaoru Decoction Ameliorated Type II Collagen-Induced Arthritis in Rats <i>via</i> Regulating JAK2–STAT3 and NF-κB Signaling Pathway DOI Open Access

Yanfei Niu,

Qianjing Feng,

Mingxue Cui

et al.

Biological and Pharmaceutical Bulletin, Journal Year: 2024, Volume and Issue: 47(9), P. 1511 - 1524

Published: Sept. 12, 2024

Siweixizangmaoru decoction (SXD) is widely used as an anti-rheumatoid arthritis (RA) in Tibet, however, the specific anti-inflammatory mechanism of SXD still unclear. This research attempts to examine efficacy and possible mechanisms treating RA. The primary chemical components were identified using UHPLC-Q-Exactive Orbitrap MS. We established a lipopolysaccharide (LPS)-induced RAW264.7 macrophage inflammatory injury model explore validated it through vivo experiments. According our vitro well vivo, exhibits qualities. can suppress nitric oxide (NO) pro-inflammatory factor production cells activated by LPS. underlying this effect might be connected janus tyrosine kinase 2-signal transducer activator transcription 3 (JAK2/STAT3) nuclear factor-κB (NF-κB) signaling pathways. In alleviates joint swelling, decreases generation factors serum, lowers oxidative stress, improves damage. short, degeneration symptoms associated with RA regulating inflammation via suppression NF-κB JAK2/STAT3 pathway activation.

Language: Английский

Citations

0
A prospective randomized-controlled non-blinded comparative study of the JAK inhibitor (baricitinib) with TNF-α inhibitors and conventional DMARDs in a sample of Egyptian rheumatoid arthritis patients DOI Creative Commons

E. Mahmoud,

Abdullah Radwan,

Sahar A. Elsayed

et al.

Clinical Rheumatology, Journal Year: 2024, Volume and Issue: 43(12), P. 3657 - 3668

Published: Oct. 31, 2024

Abstract To evaluate the efficacy of baricitinib compared to TNF-α Inhibitors and conventional DMARDs (cDMARDs) in patients with RA. Our study included 334 RA classified into 3 groups: first receiving baricitinib, second Inhibitors, third cDMARDs. Patients were evaluated at baseline, week 12, 24 using TJC, SJC, VAS, DAS28, CDAI, HAQ-DI. Larsen score was measured baseline weeks. The response therapy assessed weeks 12 ACR 20, 50, 70 criteria. Emerging treatment side effects monitored. showed significant improvement regarding all outcome measures 24. In addition, comparable TNF except which higher group. Furthermore, group significantly better comparison cDMARDs most common infection, GIT, CVS complications. inhibitors infection skin had least effects, mostly GIT Baricitinib is an effective drug for treating refractory cDMARDs, improving disease activity functional status reducing progression structural joint damage. It has a safety profile Inhibitors. Multicenter studies are recommended support our results. Key Points • therapeutic choice rheumatoid arthritis treated status. Bricitinib delayed radiographic damage more effectively than that inhibitors.

Language: Английский

Citations

0